1-(2-hydroxyethyl)-3-tert-butylurea

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机碳酸及其衍生物
• 英文名称: 1-(2-hydroxyethyl)-3-tert-butylurea
• 英文别名: 1-(2-Hydroxyethyl)-3-t-butylurea；1-tert-butyl-3-(2-hydroxyethyl)urea
• 化学式: C₇H₁₆N₂O₂
• mdl: MFCD04123489
• 分子量: 160.216
• InChiKey: AVPJNLYWMUHKJP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.3
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.857
• 拓扑面积：
  61.4
• 氢给体数：
  3
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  C.I.酸性橙108 、 叔丁基异氰酸酯 以 乙醚 为溶剂， 以93%的产率得到1-(2-hydroxyethyl)-3-tert-butylurea
  参考文献：
  名称：

  摘要：

  A series of 1-(2-hydroxyethyl)- and 1-(3-hydroxyethyl)-3-substituted ureas and thioureas were synthesized. 1-(3-Hydroxyerhyl)-3-acylthioureas were shown to be specific substrates for alcohol dehydrogenase in vitro.

  DOI：

  10.1023/a:1011385405611

文献信息

• Quinazoline Derivatives as a Multiplex Inhibitor and Method For the Preparation Thereof
  申请人：Ahn Young-Gil

  公开号：US20080318950A1

  公开（公告）日：2008-12-25

  The present invention relates to a novel quinazoline derivative and a pharmaceutically acceptable salt thereof as a multiplex inhibitor, a method for the preparation thereof, and a pharmaceutical composition and a therapeutic composition comprising same as an active ingredient. The inventive quinazoline derivative as a multiplex inhibitor can selectively and effectively inhibit diseases caused by the overactivity of a tyrosine kinase.

  本发明涉及一种新型喹唑啉衍生物及其药学上可接受的盐，作为多重抑制剂，其制备方法，以及包含其作为活性成分的药物组合物和治疗组合物。发明的喹唑啉衍生物作为多重抑制剂可以选择性和有效地抑制由酪氨酸激酶过度活性引起的疾病。
• Compositions and methods for delivery of biologically active agents
  申请人：Khoo Shui-Mei

  公开号：US20070108405A1

  公开（公告）日：2007-05-17

  The present invention provides methods and compositions for the delivery of a biologically active agent to a biological system. The compositions include the active agent and a lyotropic phase and release of the active agent to the biological system is modified by the lyotropic phase.

  本发明提供了将生物活性物质传递到生物系统的方法和组合物。这些组合物包括活性物质和亲疏水相，而亲疏水相可以调节活性物质在生物系统中的释放。
• Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors
  申请人：Nakajima Suanne

  公开号：US20070060510A1

  公开（公告）日：2007-03-15

  The present invention relates to compounds of Formula I or II, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

  本发明涉及公式I或II的化合物，或其药学上可接受的盐、酯或前药，其抑制丝氨酸蛋白酶活性，特别是丝氨酸蛋白酶NS3-NS4A的活性。因此，本发明的化合物干扰丙型肝炎病毒的生命周期，也可用作抗病毒剂。本发明还涉及包含上述化合物的制药组合物，用于治疗丙型肝炎病毒感染的患者。本发明还涉及通过给予本发明化合物的制药组合物来治疗患有丙型肝炎病毒感染的患者的方法。
• Substituted Imidazopyridazines as Lipid Kinase Inhibitors
  申请人：Capraro Hans-Georg

  公开号：US20100305113A1

  公开（公告）日：2010-12-02

  The invention relates to novel compounds of the formula I, as well as other invention embodiments related to these compounds. The compounds are e.g. useful in the treatment of the animal or human body in view of their ability to inhibit protein kinases such as especially PI3 kinase.

  本发明涉及公式I的新化合物，以及与这些化合物相关的其他发明实施方式。这些化合物可用于治疗动物或人体，因为它们能够抑制蛋白激酶，特别是PI3激酶。
• Inhibitors of phosphatidylinositol 3-kinase gamma
  申请人：AstraZeneca AB

  公开号：US10858355B2

  公开（公告）日：2020-12-08

  There are disclosed certain novel compounds (including pharmaceutically acceptable salts thereof), that inhibit phosphatidylinositol 3-kinase gamma (PI3Kδ) activity, to their utility in treating and/or preventing clinical conditions including respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), to their use in therapy, to pharmaceutical compositions containing them and to processes for preparing such compounds.

  本文公开了某些新型化合物（包括其药学上可接受的盐）、 抑制磷脂酰肌醇 3- 激酶γ（PI3Kδ）活性的化合物，它们在治疗和/或预防包括呼吸系统疾病（如哮喘和慢性阻塞性肺病（COPD））在内的临床疾病中的用途，它们在治疗中的使用，含有它们的药物组合物，以及制备此类化合物的工艺。